These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19320246)

  • 1. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
    Fofana DB; Soulie C; Maiga AI; Fourati S; Malet I; Wirden M; Tounkara A; Traore HA; Calvez V; Marcelin AG; Lambert-Niclot S
    J Antimicrob Chemother; 2013 Nov; 68(11):2515-20. PubMed ID: 23833185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural polymorphisms of integrase among HIV type 1-infected South African patients.
    Fish MQ; Hewer R; Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):489-93. PubMed ID: 20377427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.
    Myers RE; Pillay D
    J Virol; 2008 Sep; 82(18):9228-35. PubMed ID: 18596095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
    Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
    BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short Communication: HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences.
    Mikasi SG; Isaacs D; Ikomey GM; Shimba H; Cloete R; Jacobs GB
    AIDS Res Hum Retroviruses; 2021 Jan; 37(1):54-56. PubMed ID: 32640829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.